Takeda PharmaceuticalSee all their emails

U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations

A real announcement email from Takeda Pharmaceutical. Captured September 14, 2026.

Make this email yours

Migma AI designs one like it with your logo, colors, and images.

U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations email from Takeda Pharmaceutical screenshot

Captured Announcement

Takeda Pharmaceutical announces FDA acceptance of a new drug application for Zasocitinib in plaque psoriasis.

Logo at top left, corporate press release header banner with laboratory image, headline and date, text link CTA, feedback rating poll, and light grey footer.

Original email and brand assets belong to their respective owners. Design notes describe the creative, not campaign results.